Pan-immune-inflammation value in FMF patients

Abstract

Objective: Familial Mediterranean fever (FMF) is the most common disease that leads to secondary amyloidosis related to persistent subclinical inflammation in Turkish patients. Pan-immune-inflammation value (PIIV), a recently-developed index validated to predict prognoses of several malignancies. We investigated PIIV in FMF patients.

Material and Methods: We included 100 FMF patients with regular follow-ups, defined as at least two visits yearly. Demographic characteristics, prominent attack features, and treatment choices of the patients were noted. We also calculated PIIV and other inflammation-related laboratory results at attack-free periods. In the comparative analysis of quantitative data, Student's t-test (for normal distribution) and the Mann-Whitney U test (for non-normally distribution) were used. P <0.05 was accepted as a statistically significant value.

Results: A total of 100 patients were included in the study. Forty-two patients were male, whereas fifty-eight patients were female. The patients were between 18 and 69 years old, and the mean age of the study group was 39.65 ± 13.83 years. MEFV mutation analyses of eighty-six patients were present in the medical record system. Exon 10 mutations were detected in 67 (77.9%) patients, whereas non-exon 10 mutations (exon 2 and 3) were in 8 (9.3%) patients. Homozygous Exon 10 mutations were detected in 19 patients (22.1%). Although acute phase reactants, including erythrocyte sedimentation rate (ESR), c-reactive protein (CRP), and serum amyloid A (SAA), were significantly higher in patients with homozygous exon 10 mutations, there was no statistical difference in PIIV between groups.

Conclusion: The results were also similar to the recent literature in the northern part of the country. The need for biological agents and male gender was significantly higher in patients with homozygous exon 10 mutations compared to other groups.